Table 2

Patient survival—the results of univariate and multivariate analysis

	1-year survival (%)	2-year survival (%)	p Value	HR (95% CI)	p Value
VA type
TDC	91.2	77.7	0.001*	3.8 (1.6 to 8.9)	0.002
AVF	97.2	95.7	0.001*	3.8 (1.6 to 8.9)	0.002
Sex
Male	91.1	79.0	0.065*	1.7 (0.9 to 3.2)	0.069
Female	96.5	89.0	0.065*	1.7 (0.9 to 3.2)	0.069
An attempt to create an AVF or an AVF that ceased to function prior to the observed VA
Yes	95.7	87.4	0.037*	1.8 (1.1 to 3.1)	0.040
No	91.3	78.6	0.037*	1.8 (1.1 to 3.1)	0.040
Concomitant diabetes mellitus
Yes	91.2	76.7	0.021*	0.5 (0.3 to 0.9)	0.023
No	94.8	87.5	0.021*	0.5 (0.3 to 0.9)	0.023
Stroke in patient's history
Yes	94.6	72.9	0.028*	0.5 (0.3 to 0.9)	0.031
No	93.0	84.9	0.028*	0.5 (0.3 to 0.9)	0.031
Concomitant coronary heart disease
Yes	93.2	68.9	0.017*	0.5 (0.3 to 0.9)	0.019
No	93.3	88.2	0.017*	0.5 (0.3 to 0.9)	0.019
Peripheral artery revascularisation
Yes	100	57.9	0.028*	0.5 (0.2 to 0.9)	0.033
No	92.7	86.2	0.028*	0.5 (0.2 to 0.9)	0.033
VA conversion
A	86.4	64.8	<0.001*	2.8 (1.5 to 5.0)	0.001
B	97.1	95.5
C	95.0	86.5
Hypertensive kidney disease	96.0	96.0	<0.001*	0.2 (0.1 to 0.5)	0.002
Glomerulonephritis	100	100	<0.001*	0 (0 to 0.3)	0.018
The age of patients at the initiation of HD treatment (years)				1.0 (1 to 1.1)	0.037
Time from the initiation of HD treatment to the observed VA creation (months)				0.8 (0.7 to 0.9)	0.006

A: TDC as an exclusive VA; B: AVF as an exclusive VA; C: the conversion of VA from AVF to TDC.
*Log-rank (Mantel-Cox) test.
AVF, arteriovenous fistula; HD, haemodialysis; TDC, tunnelled haemodialysis catheter; VA, vascular access.